Literature DB >> 21883722

Comparison of two POLQ mutants reveals that a polymerase-inactive POLQ retains significant function in tolerance to etoposide and γ-irradiation in mouse B cells.

Yingqian Li1, Xiang Gao, Ji-Yang Wang.   

Abstract

DNA polymerase θ (POLQ) is a family A polymerase that contains an intrinsic helicase domain. POLQ has been implicated in tolerance to DNA damage but whether this depends solely on its polymerase domain remains unknown. In this study, we generated POLQ-null CH12F3 B cells by gene targeting and compared their sensitivity to DNA-damaging agents with previously established POLQ-inactive CH12F3 cells in which only the polymerase core domain was deleted. Compared with WT cells, POLQ-null and POLQ-inactive cells exhibited similarly increased sensitivity to mitomycin C, cisplatin, and ultraviolet radiation, suggesting that tolerance to these DNA-damaging agents depends largely on POLQ polymerase activity. Intriguingly, POLQ-null cells exhibited higher sensitivity than did POLQ-inactive cells to etoposide and γ-irradiation, both of which induce double-strand breaks (DSBs). This observation indicates that the polymerase-deleted POLQ, expressed in POLQ-inactive cells, retains significant function in tolerance to these agents. Class switch recombination of immunoglobulin genes, which involves repair of activation-induced cytidine deaminase (AID)-triggered DSBs, however, was unaffected in both POLQ-null and POLQ-inactive cells. These results suggest that the polymerase and other functional domains of POLQ both play important roles in tolerance to etoposide and γ-irradiation but are dispensable for AID-mediated class switch recombination.
© 2011 The Authors. Journal compilation © 2011 by the Molecular Biology Society of Japan/Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883722     DOI: 10.1111/j.1365-2443.2011.01550.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  8 in total

Review 1.  The recent advances in non-homologous end-joining through the lens of lymphocyte development.

Authors:  Xiaobin S Wang; Brian J Lee; Shan Zha
Journal:  DNA Repair (Amst)       Date:  2020-06-25

Review 2.  DNA polymerase POLQ and cellular defense against DNA damage.

Authors:  Matthew J Yousefzadeh; Richard D Wood
Journal:  DNA Repair (Amst)       Date:  2012-12-04

Review 3.  DNA polymerase θ (POLQ), double-strand break repair, and cancer.

Authors:  Richard D Wood; Sylvie Doublié
Journal:  DNA Repair (Amst)       Date:  2016-05-14

4.  Mechanism of suppression of chromosomal instability by DNA polymerase POLQ.

Authors:  Matthew J Yousefzadeh; David W Wyatt; Kei-Ichi Takata; Yunxiang Mu; Sean C Hensley; Junya Tomida; Göran O Bylund; Sylvie Doublié; Erik Johansson; Dale A Ramsden; Kevin M McBride; Richard D Wood
Journal:  PLoS Genet       Date:  2014-10-02       Impact factor: 5.917

5.  A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.

Authors:  Ana Paula Carneiro Brandalize; Lavínia Schüler-Faccini; Jean-Sébastien Hoffmann; Maira Caleffi; Christophe Cazaux; Patricia Ashton-Prolla
Journal:  BMC Cancer       Date:  2014-11-19       Impact factor: 4.430

6.  Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.

Authors:  Chun-Hua Dai; Ping Chen; Jian Li; Tin Lan; Yong-Chang Chen; Hai Qian; Kang Chen; Mei-Yu Li
Journal:  Oncotarget       Date:  2016-10-04

Review 7.  Repair of programmed DNA lesions in antibody class switch recombination: common and unique features.

Authors:  Yafang Shang; Fei-Long Meng
Journal:  Genome Instab Dis       Date:  2021-03-26

8.  Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells.

Authors:  T Goullet de Rugy; M Bashkurov; A Datti; R Betous; L Guitton-Sert; C Cazaux; D Durocher; J S Hoffmann
Journal:  Biol Open       Date:  2016-10-15       Impact factor: 2.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.